The approved drugs include bortezomib, cisplatin, doxorubicin, docetaxel, fluorouracil, and paclitaxel, which are crucial for cancer treatment, according to a company statement.

Venus Remedies gets marketing approval for six chemotherapy drugs from Philippines

“The company has secured marketing authorisation from Serbia for gemcitabine and docetaxel, widely used chemotherapy drugs beneficial in the treatment of various types of cancer,” the company said in a regulatory filing.

Venus Remedies trades 2% up on approval to market cancer drugs in Serbia

Venus Remedies has launched its R&D drug Elores, which is effective against multiple drug-resistant Gram-negative bacteria and has been patented in 46 countries including Japan and the US, in Oman’s $7.5m antimicrobial market. Elores is aiming to capture 0.5% of the segment by 2025.

Venus Remedies launches flagship R&D drug Elores in Oman

With this, the company has secured 506 marketing approvals for its oncology products across 76 countries.

Venus Remedies gets market authorisations for cancer drugs from Philippines, Praguay, Georgia, Moldova

SEBI recently introduced ESM framework for micro and small companies with market cap below 500 crore, leading to trading restrictions based on price variations.

Venus Remedies stops trading as sharp rally triggers enhanced surveillance measures by Sebi

The company has secured 503 marketing approvals for its oncology products across 75 countries.

Venus Remedies jumps 3% on nod to operate in 4 foreign markets

With this, it has secured 503 marketing approvals for its oncology products across 75 countries, a company statement said.

Venus Remedies gets marketing approval from different countries for chemotherapy drugs

Will be able to capture a 10% share in the $6.34-million meropenem market of Spain

Venus Remedies gets nod to sell generic antibiotic in Spain

The company got its approval through its German subsidiary for 500 mg, 1 g and 2 g injections of meropenem, which is used in treating skin and abdominal infections

Venus Remedies hits 5% upper circuit on drug approval in Spain

The share touched a 52-week high of Rs 263.55 and a 52-week low of Rs 145 on May 31, 2023 and February 8, 2023, respectively.

Venus Remedies share price gains on GMP Certification from Ukraine

In a statement here, the company said it received certification for Meropenem 500mg, Meropenem 1000mg, Meropenem 2000mg, Oxaliplatin 5mg/ml, Paclitaxil 6mg/ml, Cisplatin 1mg/ml, Imipenem/Cilastatin 500mg/500mg of Carbapenem.

Venus Remedies gets GMP certification from Ukraine for Carbapenem, oncology facilities in HP

The creamy layer - amongst the top performing stocks

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is underpriced and is not in the overbought zone

Current price is less than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

The stock has a moderate number of red flags

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Venus Remedies Limited is engaged in pharmaceutical product manufacturing business. The Company provides formulations and manufactures dosage injectables.